The recently-released National Population and Housing Census 2024 indicates that Uganda is making commendable steps towards ...

With only seven members, iGEM Eindhoven forms a small but determined student team that aims to help shape the future of ...

A nationwide shortage of BCG vaccines is leaving Kenyan newborns vulnerable to TB, a disease with high prevalence, health ...

Imagine a career in a field you can’t imagine. Dominique Constantini parlayed her commitment to immunology to meeting unmet ...

A combination of two existing chemotherapy drugs has been used to fight bladder cancer successfully for the first time in Singapore. This new union of the two “off-label” drugs – gemcitabine and ...

In vivo perturbations and single-cell RNA-seq reveal cell-type-specific STAT1-IFNg signaling in regulation of trained immunity in tissue-resident immune cells.

They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.

JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer ...

J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced significant progress in its ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding three areas of its ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...